Search Results - "Dib, Elie G."

Exploring geriatric assessment‐driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer by Brick, Rachelle, Jensen‐Battaglia, Marielle, Streck, Brennan P., Page, Lindsey, Tylock, Rachael, Cacciatore, Jenna, Mustian, Karen, Khatri, Jamil, Giguere, Jeff, Dib, Elie G., Mohile, Supriya, Culakova, Eva

“…Abstract Background Older adults with advanced cancer experience functional disability that warrants rehabilitation services; however, evidence indicates…”
Get full text

The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer by Gilmore, Nikesha, Kehoe, Lee, Bauer, Jessica, Xu, Huiwen, Hall, Bianca, Wells, Megan, Lei, Lianlian, Culakova, Eva, Flannery, Marie, Grossman, Valerie Aarne, Sardari, Ronak Amir, Subramanya, Himal, Kadambi, Sindhuja, Belcher, Elizabeth, Kettinger, Jared, O'Rourke, Mark A., Dib, Elie G., Vogelzang, Nicholas J., Dale, William, Mohile, Supriya

“…Background Aging‐related deficits that eventually manifest as frailty may be associated with poor emotional health in older patients with advanced cancer. This…”
Get full text

Granulomatous hepatitis: Is it bugs, drugs, or other untoward culprits? by Shah, Neil, Dib, Elie G, Joseph, Nora, Fontana, Robert J

“…1_ws9e5z3i Kaltura…”
Get full text

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study by Cannon, Timothy L, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Chiu, Vi K, Hwang, Jimmy, Vijayvergia, Namrata, Alese, Olatunji B, Dib, Elie G, Duvivier, Herbert L, Klute, Kelsey A, Sahai, Vaibhav, Ahn, Eugene R, Bedano, Pablo, Behl, Deepti, Sinclair, Sarah, Thota, Ramya, Urba, Walter J, Yang, Eddy S, Grantham, Gina N, Hinshaw, Dominique C, Gregory, Abigail, Halabi, Susan, Schilsky, Richard L

“…Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in…”
Get full text

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma by Powell, Steven F., Mazurczak, Miroslaw, Dib, Elie G., Bleeker, Jonathon S., Geeraerts, Louis H., Tinguely, Matthew, Lohr, Michele M., McGraw, Steven C., Jensen, Ashley W., Ellison, Christie A., Black, Lora J., Puumala, Susan E., Reed, Valerie J., Miskimins, W. Keith, Lee, John H., Spanos, William C.

“…Chemoradiotherapy (CRT) for locally-advanced head and neck squamous cell carcinoma (LA-HSNCC) yields 5-year survival rates near 50% despite causing significant…”
Get full text

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study by Ganti, Apar K, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Dib, Elie G, Duvivier, Herbert L, Ahn, Eugene R, Behl, Deepti, Borghaei, Hossein, Balmanoukian, Ani S, Gaba, Anu, Li, Rui, Osei-Boateng, Kwabena, Thota, Ramya, Grantham, Gina N, Gregory, Abigail, Halabi, Susan, Schilsky, Richard L

“…The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents…”
Get more information

Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide by Dib, Elie G., Antonarakis, Emmanuel S., Wasco, Matthew J., Powell, Steven F.

Get full text

Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study by Sahai, Vaibhav, Rothe, Michael, Mangat, Pam K, Garrett-Mayer, Elizabeth, Suhag, Vijay, Dib, Elie G, Mehmi, Inderjit, Kadakia, Kunal C, Pisick, Evan, Duvivier, Herbert L, Le, Phat, Li, Rui, Michelin, David P, Wilcox, Ryan E, Grantham, Gina N, Hinshaw, Dominique C, Gregory, Abigail, Halabi, Susan, Schilsky, Richard L

“…Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in…”
Get more information

Case reports and the fight against cancer by Dib, Elie G, Kidd, Michael R, Saltman, Deborah C

“…Some of the earliest case reports describing individual patients afflicted with cancer can be traced all the way back to the papyrus records of Ancient…”
Get full text

Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer by Kleckner, Amber S, Wells, Megan, Kehoe, Lee A, Gilmore, Nikesha J, Xu, Huiwen, Magnuson, Allison, Dunne, Richard F, Jensen-Battaglia, Marielle, Mohamed, Mostafa R, O'Rourke, Mark A, Vogelzang, Nicholas J, Dib, Elie G, Peppone, Luke J, Mohile, Supriya G

“…Older patients with advanced cancer often have comorbidities that can worsen their cancer and treatment outcomes. We assessed how a geriatric assessment…”
Get more information

Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis by Dib, Elie G, Dib, Samar A, Korkmaz, Dany A, Mobarakai, Neville K, Glaser, Jordan B

“…We report a 40-year-old female patient who was admitted to the hospital because of a left ovarian mass torsion. A nonhemolytic, nonmotile Bacillus, suspicious…”
Get full text

Multifocal Myoclonus Induced by Trimethoprim–Sulfamethoxazole Therapy in a Patient with Nocardia Infection by Dib, Elie G, Bernstein, Steven, Benesch, Curtis

“…To the Editor: A 63-year-old woman with a history of non-Hodgkin's lymphoma that had been treated 25 years previously, as well as a history of hypertension,…”
Get full text

Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy by Dib, Elie G., Ifthikharuddin, Jainulabdeen J., Scott, Glynis A., Partilo, Steven R.

Get full text

Peaceful acceptance of illness among older adults with cancer by Gilbride, Elizabeth, Hryniv, Sofiia, Consagra, William, Mohile, Supriya Gupta, Yilmaz, Sule, Culakova, Eva, Canin, Beverly, Malhotra, Arul, Dib, Elie G., Onitilo, Adedayo A., Berenberg, Jeffrey L., LoCastro, Marissa, Anand, Maya, Magnuson, Allison, Loh, Kah Poh

“…12045 Background: Greater illness acceptance is associated with lower levels of psychological distress and higher rates of completion of advance care planning…”
Get full text

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004 by Yaeger, Rona, Shi, Qian, Dueck, Amylou C., Dib, Elie G., Kazmi, Syed Mohammad Ali, Alese, Olatunji B., Krishnamurthi, Smitha S., Nixon, Andrew B., Shergill, Ardaman, O'Reilly, Eileen Mary, Meyerhardt, Jeffrey A

“…TPS3641 Background: Patients with mismatch repair proficient (pMMR) BRAF V600E mutant high-risk stage II (T4) or stage III colon cancer have a substantial risk…”
Get full text

Using bioinformatic tools to examine similarities between human PDL-1 protein and common tobacco (Nicotiana tabacum) by Dib, Elie G., Hill, Nicholas, Wollard, Jessica, Yoo, Ji Woon, Dib, Joe E., Ganguly, Anutosh, Cho, Clifford

“…Abstract only 70 Background: Human CD274 receptor, known as programmed cell death 1 ligand 1 (RefSeq NP_054862.1), is an inhibitory ligand for Programmed cell…”
Get full text

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance) by Woyach, Jennifer Ann, Yin, Jun, Brown, Jennifer R., Dinner, Shira, Lozanski, Gerard, Little, Richard F., Miller, Cecelia, Damarla, Vijay Kumar, Coutre, Steve E., Ding, Wei, Hill, Brian T, Perez Burbano, Gabriela, Ruppert, Amy S., Wall, Anna K. M., Feldman, Diane, Dib, Elie G., Erba, Harry Paul, Litzow, Mark Robert, Stone, Richard M., Byrd, John C.

“…7500 Background: The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib +/- anti-CD20 antibody obinutuzumab (IO) is a standard frontline regimen for older…”
Get full text

Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study by Behl, Deepti, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Farrington, Laura Catherine, Crysler, Oxana V., Dib, Elie G., Duvivier, Herbert Leon, Hall, Michael J., Salmon, John Stuart, Alese, Olatunji B., Marr, Alissa S., Ngirailemesang, Isa, Polavaram, Latha, Thota, Ramya, Yang, Eddy Shih-Hsin, O'Lone, Raegan, Grantham, Gina N., Halabi, Susan, Schilsky, Richard L.

“…122 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with…”
Get full text

Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study by Cannon, Timothy Lewis, Rothe, Michael, Garrett-Mayer, Elizabeth, Chiu, Vi Kien, Hwang, Jimmy J., Vijayvergia, Namrata, Alese, Olatunji B., Dib, Elie G., Duvivier, Herbert Leon, Klute, Kelsey, Sahai, Vaibhav, Ahn, Eugene R, Behl, Deepti, Sinclair, Sarah, Thota, Ramya, Urba, Walter John, Yang, Eddy Shih-Hsin, Grantham, Gina N., Halabi, Susan, Schilsky, Richard L.

“…546 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with…”
Get full text

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) by Woyach, Jennifer A., Ruppert, Amy S., Perez, Gabriela, Booth, Allison M, Feldman, Diane, Dib, Elie G, Jatoi, Aminah, Le-Rademacher, Jennifer, Heerema, Nyla A., Miller, Cecelia, Lozanski, Gerard, Little, Richard F., Hill, Brian T., Ding, Wei, Stone, Richard M., Mandrekar, Sumithra J, Byrd, John C.

“…Background The phase 3 trial A041202 solidified the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a standard of care for older patients with previously…”
Get full text